Aurinia Pharmaceuticals (AUPH) Finished Goods (2023 - 2026)

Aurinia Pharmaceuticals' Finished Goods history runs 4 years deep, the most recent figure standing at $4.3 million for Q1 2026.

• Quarterly Finished Goods rose 17.84% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 million (up 17.84% YoY) and the FY2025 annual result came in at $379000.0, down 58.03% from the prior year.
• Finished Goods was $4.3 million for Q1 2026 at Aurinia Pharmaceuticals, up from $379000.0 in the prior quarter.
• Across five years, Finished Goods topped out at $4.3 million in Q1 2026 and bottomed at $379000.0 in Q4 2025.
• A 4-year average of $2.0 million and a median of $1.4 million in 2025 frame the typical range for Finished Goods.
• Annual changes were most pronounced in 2024 — Finished Goods surged 54.89% — and 2025, when it plunged 58.03%.
• Aurinia Pharmaceuticals' Finished Goods stood at $583000.0 in 2023, then jumped by 54.89% to $903000.0 in 2024, then plunged by 58.03% to $379000.0 in 2025, then soared by 1043.54% to $4.3 million in 2026.
• Business Quant data shows AUPH's Finished Goods at $4.3 million in Q1 2026, $379000.0 in Q4 2025, and $1.4 million in Q3 2025.